The Pharma Letter M&A round-up – October 2026
In October 2026, The Pharma Letter reported 12 M&A deals, including four worth over $1 billion. Shionogi (TYO: 4507) acquired IntraBio for $2 billion. Viatris (Nasdaq: VTRS) agreed to buy Pacira BioSciences (Nasdaq: PCRX) for $1.65 billion. Ferring Pharmaceuticals agreed to pay up to $1.38 billion for Gameto. Merck KGaA (ETR: MRK) acquired Silence Therapeutics (Nasdaq: SLN) for about $1.3 billion.
How this was made
The 30-second read
Why it matters
These disclosed agreements provide concrete transaction values and target assets, which typically drive immediate repricing for targets and deal-premium expectations for acquirers, subject to closing and regulatory risk.
Market read
Material, named M&A terms can drive short-term repricing in deal-linked equities, especially targets, while acquirers may see sentiment swings based on integration and funding assumptions.
What to watch
The article does not specify deal structure details (financing, milestones, closing timeline, regulatory strategy). Those omissions can materially change probability-weighted valuation and near-term trading behavior.
Background
The Pharma Letter summarizes October’s pharma M&A activity, highlighting four deals above $1 billion including acquisitions by Shionogi, Viatris, Ferring, and Merck KGaA.
Ticker impact
Viatris agreed to buy non-opioid pain specialist Pacira BioSciences for $1.65 billion in cash.
Likely modest positive to neutral reaction as investors weigh growth/pipeline benefits against cash use and execution risk.
The disclosed consideration is material and directly ties to a specific therapeutic area, but the article provides no guidance, financing structure, or expected closing timeline.
Pacira BioSciences is the target in Viatris’ $1.65 billion cash acquisition agreement.
Likely upward pressure as the market prices the acquisition premium and deal probability.
The article states a concrete cash purchase price and identifies Pacira as the acquired entity, which is typically immediately supportive for the target’s equity.
Merck KGaA agreed to acquire UK RNA interference company Silence Therapeutics for about $1.3 billion.
Likely positive bias as investors react to pipeline enrichment, with volatility around RNAi clinical and regulatory outcomes.
The deal is sizable and includes a named candidate (divesiran), but the article lacks details on trial status, regulatory progress, or financing.
Silence Therapeutics agreed to be acquired by Merck KGaA for about $1.3 billion, gaining the polycythemia vera candidate divesiran.
Likely upward reaction as the market incorporates the acquisition value and deal completion probability.
The article provides a specific acquisition consideration and identifies Silence as the acquired company, which is directly valuation-relevant for the target.
Market effects
Large pharma and biotech M&A signals continued appetite for late-stage assets and platform technologies (rare disease, pain, RNAi, fertility).
Cross-border deals can shift sentiment across US and European pharma, but the article does not provide market-wide moves.
Reinforces global consolidation trends in specialty pharma and biotech platforms, potentially affecting deal comps and valuation expectations.
Counterpoint
Deal announcements can fade if financing, regulatory hurdles, or competitive bidding risk emerges; initial optimism may reverse before definitive agreements and approvals.
Key entities
- acquirerShionogi
Japanese pharma major agreeing to acquire IntraBio for $2 billion upfront, adding Aqneursa.
- acquirerViatris
Agreed to buy Pacira BioSciences for $1.65 billion in cash.
- targetPacira BioSciences
Non-opioid pain specialist being acquired by Viatris for $1.65 billion.
- acquirerMerck KGaA
Agreed to acquire Silence Therapeutics for about $1.3 billion.
- targetSilence Therapeutics
RNA interference company being acquired by Merck KGaA for about $1.3 billion.
